CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Home›
Companies›
Akamis Bio›
News
Akamis Bio

Akamis Bio

Akamis Bio develops systemically administered tumor-specific immuno-gene therapies for solid tumors, initially targeting locally advanced rectal cancer.

Cambridge, MA, US🇺🇸
Founded
2010
Loading
Overview
Compare
Fundraising
Employees
News
Library

Latest News About Akamis Bio

Akamis Bio's NG-350A Shows 50% Response Rate in Locally Advanced Rectal Cancer Phase 1b Trial

MedPath Trial

Akamis Bio's NG-350A Shows 50% Response Rate in Locally Advanced Rectal Cancer Phase 1b Trial

Akamis Bio's NG-350A combined with chemoradiotherapy achieved a 50% composite response rate in the first 10 patients with...

Mar 18, 2026

Akamis Bio: $60 Million Raised For Developing Solid Tumor Treatments

Pulse 2.0

Akamis Bio: $60 Million Raised For Developing Solid Tumor Treatments

Akamis Bio - a clinical-stage oncology company using a proprietary Tumor-Specific Immuno-Gene (T-SIGn) therapy platform to deliver novel...

Dec 23, 2024

Pancreatic Cancer Patients to Receive Akamis Bio's Gene Therapy Combination in Platform Trial

genomeweb.com

Pancreatic Cancer Patients to Receive Akamis Bio's Gene Therapy Combination in Platform Trial

In the REVOLUTION trial, conducted by the Parker Institute for Cancer Immunotherapy and Cancer Research Institute, a cohort will get the...

Feb 16, 2023

Tumor gene therapy developer rebrands, emerges with $30M from blue-chip investors

Endpoints News

Tumor gene therapy developer rebrands, emerges with $30M from blue-chip investors

A transatlantic oncology outfit is entering 2023 with a new look, name, office space and $30 million to work with. Akamis Bio — named after...

Jan 6, 2023

PsiOxus doubles-down with BMS in $936M deal

MedCity News

PsiOxus doubles-down with BMS in $936M deal

PsiOxus Therapeutics has signed a second agreement with Bristol-Myers Squibb (BMS), this time for worldwide rights to its 'armed' oncolytic...

Dec 21, 2016